 Jim Brewer on Aug 17th, 2018 // No Comments
Constellation Pharmaceuticals Inc (NASDAQ:CNST) â€“ Investment analysts at Jefferies Financial Group issued their Q3 2018 EPS estimates for Constellation Pharmaceuticals in a research note issued on Monday, August 13th. Jefferies Financial Group analyst M. Raycroft forecasts that the company will earn ($0.81) per share for the quarter. Jefferies Financial Group also issued estimates for Constellation Pharmaceuticals' Q4 2018 earnings at ($0.89) EPS, FY2018 earnings at ($2.64) EPS, FY2019 earnings at ($2.52) EPS, FY2020 earnings at ($3.24) EPS, FY2021 earnings at ($0.79) EPS and FY2022 earnings at ($4.61) EPS. Get Constellation Pharmaceuticals alerts:
Constellation Pharmaceuticals (NASDAQ:CNST) last posted its quarterly earnings results on Tuesday, August 14th. The company reported ($9.96) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.71) by ($9.25). Other equities research analysts also recently issued research reports about the company. BMO Capital Markets assumed coverage on Constellation Pharmaceuticals in a research report on Monday. They set an "outperform" rating and a $19.00 price target for the company. Oppenheimer assumed coverage on Constellation Pharmaceuticals in a research report on Monday. They set an "outperform" rating and a $21.00 price target for the company. JPMorgan Chase & Co. assumed coverage on Constellation Pharmaceuticals in a research report on Monday. They set an "overweight" rating and a $17.00 price target for the company. Finally, Cann assumed coverage on Constellation Pharmaceuticals in a research report on Monday. They set an "outperform" rating and a $21.00 price target for the company.
CNST stock opened at $10.61 on Thursday. Constellation Pharmaceuticals has a 12-month low of $9.00 and a 12-month high of $12.21.
In related news, Director Anthony B. Evnin acquired 133,334 shares of Constellation Pharmaceuticals stock in a transaction on Monday, July 23rd. The shares were bought at an average price of $15.00 per share, for a total transaction of $2,000,010.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link . Also, insider James E. Flynn acquired 200,000 shares of Constellation Pharmaceuticals stock in a transaction on Monday, July 23rd. The shares were bought at an average price of $15.00 per share, for a total transaction of $3,000,000.00. The disclosure for this purchase can be found here . In the last 90 days, insiders have acquired 400,001 shares of company stock worth $6,000,015.
About Constellation Pharmaceutical